Seeing Is Believing

Currently out of the existing stock ratings of Neena Bitritto-Garg, 31 are a HOLD (21.09%), 110 are a BUY (74.83%), 6 are a SELL (4.08%).
Analyst Neena Bitritto-Garg, currently employed at DEUTSCHE BANK, carries an average stock price target met ratio of 47.11% that have a potential upside of 34.44% achieved within 177 days.
Neena Bitritto-Garg’s has documented 275 price targets and ratings displayed on 25 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ACAD, ACADIA Pharmaceuticals at 11-Feb-2025.
Analyst best performing recommendations are on SAGE (SAGE THERAPEUTIC).
The best stock recommendation documented was for ACAD (ACADIA PHARMACEUTICALS) at 12/12/2023. The price target of $25 was fulfilled within 1 day with a profit of $3.83 (18.09%) receiving and performance score of 180.92.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 07-Mar-2025
$28
$0.71 (2.60%)
29 days ago
(25-Aug-2026)
24/30 (80%)
$-2.57 (-8.41%)
206
Buy Since 21-Oct-2025
$40
$12.71 (46.57%)
$39
29 days ago
(25-Aug-2026)
0/6 (0%)
$9.43 (30.85%)
Buy Since 25-Sep-2025
$38
$10.71 (39.25%)
$29
29 days ago
(25-Aug-2026)
2/5 (40%)
$7.43 (24.30%)
574
Buy Since 17-Oct-2023
$49
$21.71 (79.55%)
$40
1 months 6 days ago
(17-Aug-2026)
2/10 (20%)
$19.99 (68.91%)
467
Buy Since 28-Feb-2024
$41
$13.71 (50.24%)
$29
1 months 11 days ago
(12-Aug-2026)
9/12 (75%)
$11.55 (39.22%)
393
What Year was the first public recommendation made by Neena Bitritto-Garg?